|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on September 12, 2002; DOI 10.1182/blood-2002-04-1207.
NEOPLASIA
From the Department of Hematology, Erasmus University
Medical Center, Rotterdam, The Netherlands.
The genetic defects underlying the pathogenesis of acute myeloid
leukemia (AML) are still largely unknown. Retroviral insertion mutagenesis in mice has become a powerful tool to identify candidate genes involved in the development of leukemia and lymphoma. We have
used this strategy with the 1.4 strain of Graffi murine leukemia virus
(MuLV), which predominantly causes myeloid leukemias. Here, we report
that Graffi-1.4-induced AML frequently harbors virus integrations in
the gene encoding the transcription factor Yin Yang 1 (YY1). These
integrations occurred in both orientations, and all were located in the
5' promoter region of the gene, 0.5 to 1.5 kb upstream of the major
transcriptional start site. Luciferase reporter assays showed that
virus integration in this region increases promoter activity and
renders it independent of a functional binding site for Sp1, a major
transcriptional regulator of YY1. We used the murine 32D model to study
the consequence of perturbed YY1 expression for myelopoiesis. YY1
protein levels were high in 32D parental cells maintained in
interleukin-3-containing medium, but they dropped when the cells were
induced to differentiate by granulocyte-colony-stimulating factor
(G-CSF). Strikingly, G-CSF-induced neutrophilic differentiation was
reduced in 32D cell transfectants ectopically expressing YY1. In
similar experiments on primary bone marrow cells, enforced YY1
expression blocked the outgrowth of CFU-GM colonies. Increased YY1
expression was seen in some cases of human AML. Collectively, these
data imply a possible role of perturbed expression of YY1 in the
development of AML through interference with the myeloid
differentiation program in the leukemic progenitor cells.
(Blood. 2003;101:1111-1117) Human acute myeloid leukemia (AML) is a
heterogeneous group of diseases with a variable treatment outcome. It
is now well established that responses to different forms of therapy
depend to a significant extent on the presence of certain genetic
defects in the leukemic cells. For instance, chromosomal abnormalities t(8;21) and inv(16)t(15;17) are now being used as important prognostic indicators in AML.1 However, it has also become clear from in vitro and in vivo models that, when isolated, these defects are
insufficient to cause leukemia but that additional "hits" in as yet
largely unidentified regulatory genes are required for full leukemic
transformation of hematopoietic cells.2,3 In addition, in
the significant proportion of AML patients who do not have cytogenetic
abnormalities, the genes involved in the pathogenesis of the disease
remain elusive. Retroviral insertional mutagenesis has become a
powerful tool to identify genes implicated in leukemogenesis and
lymphomagenesis.2-4 In the past, this method has been
tedious, but recently developed strategies using inverse polymerase
chain reaction (PCR), direct nucleotide sequencing, and database
screening now allow for a rapid and large-scale identification of
potential disease genes.4 Importantly, a number of genes identified by this strategy have also been shown to play a role in
human hematopoietic malignancies.4-9
Graffi murine leukemia virus (Graffi-MuLV) is an ecotropic retroviral
complex causing leukemias in mice.10 This viral complex does not contain oncogenic sequences, but it deregulates genes because of proviral integrations. A subclone of this complex, the
Graffi-1.4 strain, predominantly induces myeloid
leukemias.10 In these leukemias, known proto-oncogenes
such as c-myc, Pim-1, Fli-1, and Spi-1 are rarely
affected,11 indicating that other genes involved in
Graffi-1.4 MuLV-induced leukemias remain to be discovered.
Yin Yang 1 (YY1, NF-E1, delta, UCRBP, CF1) is a transcription factor of
the GLI-Krüppel zinc finger protein family that controls many
cellular processes.12-14 Targeted disruption of the
YY1 gene leads to embryonic lethality in mice from severe
defects in the development of the embryonic and extraembryonic
tissues.15 The YY1 gene spans 23 kb comprising
5 exons and encodes a protein of 44 kDa. The gene is located on human
chromosome 14q32 and on mouse chromosome 12 and is structurally highly
conserved among these species (95% homology at mRNA
level).16 Transcription of the YY1 gene is
tightly controlled. Besides a major transcriptional start site, the
existence of 10 alternative start sites in a (C+G)-rich region lacking
a TATA box have been reported.17 YY1 expression is
controlled by the transcription factor Sp1, which is expressed in many
cell types, including hematopoietic cells.17,18
YY1 has been reported to activate or repress transcription of a large
variety of cellular and viral genes.13,14,19 Additionally, YY1 regulates gene expression in a cell-cycle-dependent fashion. This
may, at least in part, be due to a control mechanism involving the
retinoblastoma protein (Rb), which releases YY1 in the S-phase of the
cell cycle.20 The transcriptional activity of YY1 is positively regulated through acetylation of the protein by p300 and
PCAF and is negatively regulated by deacetylation by histone deacetylases HDAC1, HDAC2, and HDAC3.21
In this paper, we report that the YY1 promoter region is a frequent
target for integration of Graffi-1.4 MuLV and show that the regulation
of YY1 expression is perturbed and becomes independent of Sp1
regulation as a result of these integrations. We further show that
ectopic expression of YY1 has a negative effect on myeloid differentiation in a cell line model and prevents the outgrowth of
myeloid progenitors from primary bone marrow cells. Finally, we present
data indicating that in certain cases of human AML, YY1 expression is
significantly increased compared with healthy bone marrow cells. Based
on these findings, we suggest that the deregulation of YY1 expression
can contribute to myeloid leukemia by interfering with the normal
myeloid differentiation program.
Graffi-1.4 MuLV-induced leukemias
Immunophenotyping of the leukemic cells
Production of retroviral vectors The plasmid pCMV-HA-YY1, containing hemagglutinin (HA)-tagged full-length human YY1 cDNA (a gift from Dr Y. Shi, Department of Pathology, Harvard Medical School, Boston, MA) was digested with XbaI and ApaI, and the HA-YY1 fragment was blunted and ligated into the HpaI site of pLNCX and pBabe retroviral vectors.23,24 PhoenixA packaging cells (from G. Nolan, Stanford, CA) were transfected with pLNCX-HA-YY1 or pBABE-HA-YY1 (Protection Mammalian Transfection Systems E-1200; Promega, Madison, WI). Supernatants containing high-titer, helper-free recombinant virus were harvested from 80% confluent producer cells cultured for 16 to 20 hours in Dulbecco modified Eagle medium, (DMEM; Gibco-BRL, Breda, The Netherlands) supplemented with 5% fetal calf serum (FCS), penicillin (100 IU/mL), and streptomycin (100 ng/mL). To determine titers of BABE-HA-YY1 and BABE control virus, the virus particles were pelleted by ultracentrifugation at 41 000 rpm (XL-90; Beckman, Mijdrecht, The Netherlands), and RNA was extracted with phenol (pH = 4.0) and spot-blotted on nitrocellulose filters. This blot was hybridized with a BABE-specific probe (SV40 fragment, BamHI-HindIII digest).Cell culture and retroviral gene transfer 32D cells. The interleukin-3 (IL-3)-dependent murine myeloid cell line 32D25 containing the human wild-type G-CSF receptor (32D-WT1) were expanded and differentiated as described.26 32D-WT1 cells were infected with pLNCX-HA-YY1 virus and selected with G418 (Gibco-BRL). Several independent clones were expanded for further analysis. Bone marrow cells. Hematopoietic cells were harvested from the femurs and tibiae of 8- to 12-week-old FVB mice as described.27 After depletion of adherent cells, the remaining cells were fractionated on a Percoll gradient (AB 17-0891-01; Amersham Pharmacia Biotech, Uppsala, Sweden). Fraction 1 (density 1.058/1.0645) containing the earliest hematopoietic progenitor cells28 was collected. Cells were washed twice in Hanks buffered salt solution (HBSS)/5% FCS/0.5% bovine serum albumin (BSA) and then were prestimulated for 2 days at a final concentration of 5 × 105 cells/mL in Cell Gro (SCGM BE SP047; Boehringer Ingelheim Bioproducts Partnership Heidelberg, Germany) supplemented with a cytokine cocktail composed of murine (m) IL-3 (10 ng/mL), human (h) Flt3-ligand, human thrombopoietin (hTPO), murine stem cell factor (mSCF; 100 ng/mL) and granulocyte macrophage-colony-stimulating factor (GM-CSF; 2 U/mL). Retroviral infection was performed in culture dishes (Falcon 1008; Becton Dickinson) coated with the recombinant fibronectin fragment CH-296 (Takara Shuzo T100A/B; Otsu, Japan)29 at a concentration of 12 µg/mL. Before adding the bone marrow cells, the dishes were preincubated with virus supernatant (BABE-HA-YY1 or empty BABE) for 30 minutes at 37°C. Subsequently, bone marrow cells were resuspended and mixed with fresh virus supernatant in a 1:1 ratio, and a fresh cytokine cocktail was added. Cells (5 × 105) were cultured overnight at 37°C and 5% CO2. Virus supernatant and cytokine cocktail were refreshed again the next day, and cells were cultured for another 24 hours. Colony assay. Bone marrow cells were plated at densities of 1 to 5 × 104 cells/mL per dish in triplicate in methylcellulose medium supplemented with 30% fetal bovine serum (FBS), 1% BSA, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, and GM-CSF (20 U/mL), with or without 2.5 µg/mL puromycin (Sigma, Zwijndrecht, The Netherlands) to evaluate the infection efficiency of the different retroviruses. Colonies consisting of more than 50 cells were counted on day 7 of culture. Promoter activity assay The YY1 promoter-containing subclone p SS4.5 of
 2417 was digested with restriction enzymes
MLuI and BglII. This YY1 promoter fragment was
cloned in the luciferase reporter plasmid pGL3 (Promega). The
Graffi-1.4 MuLV long terminal repeat (LTR) sequence was cloned in both orientations in the HpaI site. The Sp1 site was
mutated with the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) by using primer SPIMUTF (5' GGACGGTTCGGGGCGAGAGC 3') and
primer SPIMUTR (5' GCTCTCGCCCCGAACCGTCC 3'). As a positive control,
pRSV-Luc30 was used. pRSV- -galactosidase (a gift from C. Berrevoets, Erasmus University, Rotterdam, The Netherlands) was used
for reference. Empty pGL3 vector served as a negative control.
Luciferase assays were performed in HEK 293 cells. Cells were
transfected by CaPO4 precipitation31 with a
mixture of 5 µg derived pGL3 plasmid containing different promoter
sequences and 2.5 µg pRSV--galactosidase, supplemented with empty
vector, to a total amount of 20 µg total plasmid per milliliter.
Luciferase assays were performed as described,26 and
activities were calculated in arbitrary units, relative to
-galactosidase expression.
Twenty-five microliters cell lysate was mixed with 75 µL ONPG solution (0.028 g 2-nitro-phenyl-galacto-pyranosid; Boehringer-Mannheim, Almere, The Netherlands), 50 mL P-buffer (100 mM phosphate buffer, pH 7.0), 10 mM MgSO4, 2.7 mM). Samples were incubated at 37°C for 1 hour. The extinction was measured at 450 nm in a Bio-Rad 450 microplate reader (Bio-Rad, Richmond, CA). Inverse PCR on Graffi-1.4 MuLV-induced leukemias Genomic DNA from the primary tumors was digested with HhaI. After ligation (Rapid ligation kit; Roche Diagnostics, Mannheim, Germany), a first PCR was performed using Graffi-1.4 MuLV (LTR) specific primers L1 (5' TGCAAGATGGCGTTACTGTAGCTAG 3') and L2 (5' CCAGGTTGCCCCAAAGACCTG 3') (cycling conditions were 1 minute at 94°C, 1 minute at 65°C, and 3 minutes at 72°C; 30 cycles). For the second nested PCR, the primers L1N (5' AGCCTTATGGTGGGGTCTTTC 3') and L2N (5' AAAGACCTGAAACGACCTTGC 3') (15 cycles) were used. The PCR reaction mixture contained 10 mM Tris(tris[hydroxymethyl]aminomethane)-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 µM dNTP, 10 pmol each primer, and 2.5 U Taq polymerase (Pharmacia, Uppsala, Sweden). PCR fragments were analyzed on a 1% agarose gel and cloned in the TA cloning vector (Invitrogen BV, Carlsbad, CA) according to standard procedures.Detection of virus integration in the YY1 gene by specific nested PCR To determine the orientation and localization of the Graffi-1.4 provirus in the YY1 gene in an extended panel of leukemias, nested PCR was performed on 1 µg genomic DNA from primary tumors. For the first PCR, YY1 promoter region-specific primers Y1 (5' AGGAATCAGGAGCAGAAGAAAGTTTTGGGA 3') and Y2 (5' CAATAAAGTCTGCTCTGACGAGAAACGCC 3'), in combination with Graffi-1.4 MuLV LTR-specific primers L1 and L2 were used. Cycling conditions were 1 minute at 94°C, 1 minute at 65°C, and 3 minutes at 72°C, for 30 cycles. For the second PCR, the nested primers Y1N (5' AAACTCTCTGACTTACCTCCCTCTCCAAAGA 3') and Y2N (5' GTTCGTTTTGCCTTTACTCGTTACTCGGG 3'), in combination with the nested primers L1N and L2N (30 cycles), were used. The obtained PCR products were analyzed by Southern blotting. To determine the orientation of the Graffi-1.4 provirus, the blots were hybridized with radiolabeled Y1P (5' AAAACCTGCACAAGGACACCTTGCTAAGTATGTTT 3') and Y2P (5' AGCACACGGTCGGCTACGCTCCGTCCGCTACCGCA 3') at 45°C in Church buffer (0.5 M phosphate buffer, pH 7.2, 7% [wt/vol] sodium dodecyl sulfate [SDS], 10 mM EDTA [ethylenediaminetetraacetic acid]) overnight. Signals were visualized by autoradiography according to standard procedures.Nucleotide sequencing PCR products were cloned in TA cloning vector and sequenced with the M13 forward primer (5' GACCGGCAGCAAAATG 3') and M13 reverse primer (5' CAGGAAACAGCTATGAC 3') using an ABI 3100 sequencer (Perkin Elmer, Nieuwerkerk a/d IJssel, The Netherlands). Virus-flanking genomic sequences were identified using the National Center for Biotechnology Information (NCBI) database.Western blotting Lysates of 32D cells were prepared and subjected to Western blotting as described previously.32 Antibodies used to visualize YY1 were goat anti-YY1 (Santa Cruz Biotechnology, CA) or rabbit anti-HA (Y-11, sc-805) for HA-tagged YY1. Rabbit anti-Sp1 (a gift from Dr G. Suske, Philipps-University, Marburg, Germany) was used for the detection of Sp1. Goat anti-actin (I-19, sc-1616; Santa Cruz Biotechnology) was used to control for equal loading of lysates.Real-time quantitative PCR on human AML samples Human AML cells were obtained following informed consent and were purified as previously described.33 These purified blast fractions consisted of more than 95% myeloblasts. Total RNA was extracted with guanidinium thiocyanate and was purified by cesium chloride gradient centrifugation. RNA was transcribed into cDNA under standard conditions using Superscript (Life Technologies, Merelbeke, Belgium) and random hexamers. Real-time PCR amplification (ABI PRISM 7700 Sequence Detector; PE Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) was performed in a mix of 50 µL containing 2 µL cDNA, 250 µM dNTP (Amersham Pharmacia Biotech, Roosendaal, The Netherlands), 3 mM MgCl2, 15 pmol primers, 200 nM Taqman probe, labeled 5' with reporter dye FAM (6-carboxy-fluorescein) and 3' with quencher dye TAMRA (6-carboxy-tetramethyl-rhodamine; Eurogentec, Maastricht, The Netherlands), 1.25 U AmpliTaq Gold (PE Applied Biosystems), 5 µL 10 × buffer A (PE Applied Biosystems), and 30 µL H2O. Cycling conditions were 2 minutes at 50°C and 10 minutes at 95°C, followed by 45 cycles of denaturation (15 seconds at 95°C), and annealing/extension (1 minute at 60°C). For YY1, forward primer (5' ATACCTGGCATTGACCT 3') and reverse primer (5' TGAGGGCAAGCTATTGT 3') were used. The YY1 Taqman probe was 5' GAATGAAGCCAAGAAAAATTAAAGAAGATGT 3'. The housekeeping gene porphobilinogen deaminase (PBGD) was taken as endogenous reference (PBGD forward primer 5' GGCAATGCGGCTGCAG 3'; PBGD reverse primer 5' GGGTACCCACGCGAATCAC 3'; PBGD Taqman probe 5' CATCTTTGGGCTGTTTTCTTCCGCC 3'). All samples were tested in duplicate, and average values were used for quantification. The expression of YY1 in patient samples relative to YY1 expression in healthy bone marrow (n = 6) was calculated according to manufacturer's instructions (user bulletin 2; ABI PRISM 7700 Sequence Detector; PE Biosystems).
Graffi-1.4 MuLV-induced leukemias Leukemias developed 4 to 6 months after subcutaneous injection of newborn FVB/N mice with Graffi-1.4 MuLV. Forty-eight of 59 (81%) leukemias analyzed exhibited morphologic characteristics of myeloid cells. Blast cell percentages in the bone marrow ranged from 24% to 90%, with an average of 48%. Leukemia cells expressed immunophenotypic marker profiles consistent with their myeloid appearance for example, ER-MP54+, ER-MP58+,
CD3 , GR-1+. Six leukemias with blastlike
morphology showed no immunophenotypic differentiation markers,
suggesting that these tumors represented immature leukemias. Only 3 leukemias were of T-lymphoid origin (CD3+/MP58/Thy1+), and 2 showed
mixed myeloid and erythroid features
(Ter119+/ER-MP58+/F4/80+). These
results demonstrate that Graffi-1.4 MuLV infection predominantly induces myeloid leukemia in FVB/N mice.
Virus integrations in the YY1 gene Inverse PCR was used to identify genomic sequences flanking Graffi1.4 MuLV integrations (Figure 1A). Integrations were found in several genes previously demonstrated to be involved in MuLV-induced leukemias (eg, Notch-1, Nf1, p53, Fli-1, Evi-1) and in several novel loci (S.J.E. et al, manuscript in preparation). One of these newly identified integrations occurred in the YY1 locus, approximately 0.8 kb upstream of the transcriptional initiation site. In a subsequent analysis on independent cell samples using nested PCR with LTR and YY1 primers (Figure 1B-C), we found 23 integrations in the same region, 0.5 to 1.5 kb upstream of the transcriptional start site, in 14 of 20 leukemias tested. Integrations occurred in both orientations at an approximately equal ratio. Representative examples of these integrations are shown in Figure 1D. Searches for virus integrations in other parts of the gene using appropriate primer sets were negative (data not shown). It is of note that in some leukemia samples multiple integrations were detected, indicating that the Graffi-1.4 MuLV-induced leukemias are oligoclonal.
Integration of Graffi-1.4 MuLV LTR deregulates YY1 transcription Because integration of the virus occurred in both orientations, we considered it most likely that viral enhancer sequences in the LTR cause increased YY1 transcription in these types of leukemia. Integration in the promoter region of a gene, however, does not always result in alterations in expression. For instance, the common ecotropic virus integration 12 (Evi12) is located approximately 1 kb upstream of the transcriptional start site of the Tra1/Grp94 gene but does not modulate its expression.34 We first compared YY1 expression in the murine leukemias with and without virus integration by Northern and Western blot analyses but found no major differences between the groups (data not shown). However, because virally induced leukemias are oligoclonal2,4 (and S.J.E. et al, unpublished data), abnormalities in expression of YY1 in a subset of leukemia cells might go undetected by these techniques. As an alternative approach, we introduced the Graffi-1.4 LTR in the Hpa1 site at position 1417 in the YY1 promoter and quantified transcriptional activity using a transient reporter assay
(Figure 2). Twofold higher YY1 promoter
activity was measured following insertion of the Graffi-1.4 MuLV LTR,
irrespective of the orientation of the LTR (Figure 2). Because an
Sp1-binding site at position 48 to 39 has previously been shown to
be important for the induction of YY1 transcription,17 we
also studied the effects of insertion of the Graffi-1.4 MuLV LTR after
disruption of this site. Although mutation of the Sp1-binding site
resulted in a 50% reduction of normal promoter activity, the enhanced
promoter activity caused by the integration of the LTR sequence was not affected (Figure 2). This result demonstrates that virus integration causes enhanced and Sp1-independent transcription of YY1.
Ectopic expression of YY1 blocks G-CSF-induced neutrophilic differentiation of 32D cells The observation that integration of Graffi MuLV LTR alters the expression of YY1 in murine acute myeloid leukemia raised the question whether perturbed YY1 expression might affect myeloid cell differentiation. We have previously developed 32D cell clones expressing human G-CSF receptors (32D-WT1 cells) as a model to study neutrophilic differentiation.26 Endogenous YY1 levels are high in parental 32D-WT1 cells cultured in IL-3-containing medium, under which conditions the cells remain immature (Figure 3). However, on transfer of the cells to a G-CSF-containing medium, in which cells undergo neutrophilic differentiation, YY1 protein levels declined from day 2 onward and remained low for the entire culture period (Figure 3). In view of the regulatory role of Sp1 in YY1 expression, we also looked at Sp1 levels and found that expression of Sp1 was down-regulated in the same time frame after switching the cells to G-CSF. These results raise the possibility that YY1 levels were reduced as a consequence of lowered Sp1-controlled transcription. To determine the consequences of perturbed YY1 expression for myeloid cell development, we ectopically expressed HA-tagged YY1 in these cells. As expected, YY1 expression in 32D-HA-YY1 cells remained high after the cells were switched to G-CSF (Figure 4A). Growth rate and morphology of 32D-HA-YY1 cells cultured in IL-3-containing medium were similar to nontransduced control cells (data not shown). Strikingly, when 32D-HA-YY1 cells were switched to G-CSF-containing medium, neutrophilic differentiation was markedly reduced (Figure 4B-C). Instead, cells with a blastlike morphology expanded exponentially for 8 days in these cultures (Figure 4B) and rapidly died thereafter as a result of apoptosis (data not shown). Thus, sustained YY1 expression prevented G-CSF-induced myeloid differentiation of 32D cells without affecting the apoptotic response that normally accompanies G-CSF-induced differentiation.
Ectopic expression of YY1 blocks CFU-GM colony formation The above-mentioned experiments indicated that constitutive expression of YY1 interferes with G-CSF-induced myeloid differentiation in 32D cells. We next wanted to investigate how perturbed expression of YY1 affects the outgrowth of primary myelomonocytic progenitor cells (granulocyte macrophage-colony-forming unit [CFU-GM]). To this end, we retrovirally transduced mouse bone marrow cells with BABE-HA-YY1 or empty BABE virus and plated these in GM-CSF-containing colony assays. Notably, control bone marrow cells were subjected to equivalent titers of control virus (Figure 5A) to exclude that differences in colony outgrowth were caused by variations in transduction efficiencies. Strikingly, GM-CSF-induced colony formation by HA-YY1-transduced bone marrow cells was almost completely blocked (Figure 5B). This result suggests that perturbed expression of YY1, instead of interfering with differentiation, causes a growth arrest or results in premature apoptosis of CFU-GMs or their direct progeny.
YY1 expression in human AML An important question is whether increased levels of YY1 expression can also be found in human AML cells, which would be suggestive of a possible involvement of abnormal YY1 expression in human disease. We performed real-time quantitative PCR on cDNAs from 94 patients with AML and 6 healthy volunteers. As shown in Figure 6, YY1 transcript levels in most patients did not significantly differ from healthy bone marrow cells. However, in 13 patients, mRNA levels significantly exceeded those of the healthy bone marrow controls.
In this study, we demonstrated that the gene encoding the transcriptional regulator YY1 is located in a new common virus integration site in Graffi-1.4 MuLV-induced myeloid leukemia. The integrations occurred exclusively in the 5' promoter region of the gene, 0.5 to 1.5 kb upstream of the major transcriptional start site. Data from luciferase reporter assays strongly suggested that these integrations result in the dysregulation of YY1 expression. The pattern of virus integrations indicated that Graffi-1.4 MuLV-induced leukemias are oligoclonal, which is consistent with observations on leukemias induced by other MuLVs2,4 (and S.J.E. et al, unpublished data). The YY1 gene has already been identified once by inverse PCR as a site of retroviral integration in BXH2 leukemia/lymphoma.4 Although the exact site of integration and the type of leukemia/lymphoma were not specified in this study, the finding that the YY1 locus is affected by distinct MuLV types in different mouse strains indicates that the deregulation of YY1 may be more common in the development of various hematologic malignancies in mice. Perturbed expression of YY1 inhibited G-CSF-induced myeloid differentiation in 32D cells and prevented the clonal outgrowth of CFU-GM progenitor cells. Importantly, we observed that integration of Graffi-virus LTR sequences enhanced YY1 transcription and made it entirely independent of the recognition site for the transcription factor Sp1, which has been shown to play a pivotal role in YY1 expression. Although Sp1 expression has been reported to be high in hematopoietic cells, it is down-regulated during differentiation in many cell types.18 Indeed, we found that Sp1 declined in 32D cells after 2 days of G-CSF-induced differentiation (Figure 3). Therefore, we suggest that the bypass of Sp1 transcriptional control might be one of the mechanisms by which viral integration deregulates YY1 protein levels in leukemic cells. To establish whether down-regulation of YY1 resulted from G-CSF-induced differentiation rather than from simply switching the cells from IL-3- to G-CSF-containing medium, we also analyzed YY1 expression in IL-3-dependent Ba/F3 transfectants expressing the G-CSF-R. These cells proliferate, but they do not undergo differentiation in response to G-CSF. Because YY1 levels remained high in Ba/F3-G-CSF-R cells (data not shown) cultured in G-CSF-containing medium, it appears most likely that YY1 expression is reduced during G-CSF-induced differentiation. This notion is further supported by observations in 32D cells expressing a truncated G-CSF receptor,35 which fails to differentiate in response to G-CSF and retains YY1 expression at a level comparable to that of cells cultured in IL-3 (data not shown). A major question that remains to be addressed is how deregulation of
YY1 expression leads to the observed defects in myeloid cell
development. In view of the myriad proposed functions of YY1, multiple
possibilities can be envisaged that are not mutually exclusive. First,
it is conceivable that constitutive YY1 expression directly influences
the transcriptional regulation of genes controlling myeloid cell
development. This might be due either to the action of YY1 as a
positive regulator of transcription or to its repressor activity. With
regard to the latter, it is of interest that YY1 interacts with the
EED-EZH (enhancer of Zeste) polycomb complex (PcG) involved in
transcriptional repression. In this context, YY1 plays a role in
targeting the PcG complex to specific DNA sequences and recruiting
HDACs, which associate with both YY1 and EED.36,37
It is conceivable that the deregulation of YY1 could cause sustained
repression of multiple target genes critical for granulocytic
differentiation. In fact, altered recruitment of HDACs has already been
implicated in the deregulation of myeloid differentiation by a number
of transcription factor fusion proteins generated by specific
translocations An alternative mechanism by which YY1 can influence cell fate is by forming complexes with other protein regulators, including the c-Myc and retinoblastoma (Rb) proteins.20,42,43 A previous study has demonstrated that YY1 protein binds to Rb in a cell-cycle-dependent manner.20 In the G0/G1 phase of the cell cycle, YY1 is in a complex with Rb and cannot bind DNA but is released from this complex when cells enter into S-phase, thereby regaining its DNA-binding activity.20 The Rb protein family comprises 3 members, Rb, p107, and p130. Rb and p107, but not p130, are abundantly present in 32D cells proliferating in IL-3-containing medium. Conversely, on G-CSF-induced differentiation, Rb and p107 levels declined as p130 protein levels dramatically increased, suggesting that p130 plays a role in the induction of myeloid differentiation.44 Based on these findings, we hypothesized that the overexpression of YY1 might result in sustained binding to p130 and thereby might interfere with differentiation. Although we confirmed that YY1 can form a complex with Rb in coimmunoprecipitation assays, we have been unable to detect such an interaction of YY1 with the p130 or p107 proteins (data not shown). An important extension of this work is to determine whether abnormalities in YY1 expression may also contribute to the pathogenesis of human hematopoietic malignancies. In a first attempt to address this question, we performed real-time quantitative PCR on cDNAs from purified human AML blasts and observed that in 13 patients, the expression of YY1 was significantly elevated compared with that in healthy bone marrow controls. Although this would argue in favor of the possibility that YY1 transcript levels are abnormal in these patients, accurate comparisons are difficult because healthy bone marrow contains a mixture of cell types of different lineages in various stages of maturation. Identification of the genes controlled by YY1 during myelopoiesis and a more detailed understanding of the signaling pathways influenced by YY1 in hematopoietic cells will be required to shed light on how perturbations in these processes contribute to the development of human AML.
We thank Dr E. Rassart for the Graffi-1.4 MuLV. We also thank Drs Joanna Prasher, Bart Aarts, and Marieke von Lindern for their comments on this manuscript and Karola van Rooyen for assistance with the preparation of figures.
Submitted April 22, 2002; accepted September 3, 2002.
Prepublished online as Blood First Edition Paper, September 12, 2002; DOI 10.1182/blood-2002-04-1207.
Supported by grants from the Dutch Cancer Society and the Erasmus University Medical Center (breedtestrategie).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ivo P. Touw, Department of Hematology, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands; e-mail: touw{at}hema.fgg.eur.nl.
1.
Lowenberg B, Downing JR, Burnett A.
Acute myeloid leukemia.
N Engl J Med.
1999;341:1051-1062 2. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta. 1996;1287:29-57[Medline] [Order article via Infotrieve]. 3. Largaespada DA. Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies. Leukemia. 2000;14:1174-1184[CrossRef][Medline] [Order article via Infotrieve]. 4. Li J, Shen H, Himmel KL, et al. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet. 1999;23:348-353[CrossRef][Medline] [Order article via Infotrieve].
5.
Look AT.
Oncogenic transcription factors in the human acute leukemias.
Science.
1997;278:1059-1064
6.
Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G.
Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.
Mol Cell Biol.
2001;21:224-234 7. Fujino T, Yamazaki Y, Largaespada DA, et al. Inhibition of myeloid differentiation by Hoxa9, Hoxb8, and Meis homeobox genes. Exp Hematol. 2001;29:856-863[CrossRef][Medline] [Order article via Infotrieve]. 8. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997;11:2022-2031[CrossRef][Medline] [Order article via Infotrieve]. 9. Bruckert P, Kappler R, Scherthan H, et al. Double minutes and c-MYC amplification in acute myelogenous leukemia: are they prognostic factors? Cancer Genet Cytogenet. 2000;120:73-79[CrossRef][Medline] [Order article via Infotrieve].
10.
Ru M, Shustik C, Rassart E.
Graffi murine leukemia virus: molecular cloning and characterization of the myeloid leukemia-inducing agent.
J Virol.
1993;67:4722-4731
11.
Denicourt C, Edouard E, Rassart E.
Oncogene activation in myeloid leukemias by Graffi murine leukemia virus proviral integration.
J Virol.
1999;73:4439-4442
12.
Austen M, Luscher B, Luscher-Firzlaff JM.
Characterization of the transcriptional regulator YY1: the bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAFII55, or cAMP-responsive element-binding protein (CPB)-binding protein.
J Biol Chem.
1997;272:1709-1717 13. Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1997;1332:F49-F66[Medline] [Order article via Infotrieve]. 14. Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene. 1999;236:197-208[CrossRef][Medline] [Order article via Infotrieve].
15.
Donohoe ME, Zhang X, McGinnis L, et al.
Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality.
Mol Cell Biol.
1999;19:7237-7244
16.
Yao YL, Dupont BR, Ghosh S, et al.
Cloning, chromosomal localization and promoter analysis of the human transcription factor YY1.
Nucleic Acids Res.
1998;26:3776-3783
17.
Safrany G, Perry RP.
Characterization of the mouse gene that encodes the delta/YY1/NF-E1/UCRBP transcription factor.
Proc Natl Acad Sci U S A.
1993;90:5559-5563
18.
Saffer JD, Jackson SP, Annarella MB.
Developmental expression of Sp1 in the mouse.
Mol Cell Biol.
1991;11:2189-2199
19.
Shrivastava A, Calame K.
An analysis of genes regulated by the multi-functional transcriptional regulator Yin Yang-1.
Nucleic Acids Res.
1994;22:5151-5155 20. Petkova V, Romanowski MJ, Sulijoadikusumo I, et al. Interaction between YY1 and the retinoblastoma protein: regulation of cell cycle progression in differentiated cells. J Biol Chem. 2000;276:7932-7936[Medline] [Order article via Infotrieve].
21.
Yao YL, Yang WM, Seto E.
Regulation of transcription factor YY1 by acetylation and deacetylation.
Mol Cell Biol.
2001;21:5979-5991 22. Joosten M, Valk PJ, Vankan Y, et al. Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice. Virology. 2000;268:308-318[CrossRef][Medline] [Order article via Infotrieve]. 23. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-986[Medline] [Order article via Infotrieve]989.
24.
Morgenstern JP, Land H.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.
Nucleic Acids Res.
1990;18:3587-3596
25.
Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ.
Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.
Proc Natl Acad Sci U S A.
1983;80:2931-2935 26. de Koning JP, Soede-Bobok AA, Ward AC, et al. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene. 2000;19:3290-3298[CrossRef][Medline] [Order article via Infotrieve].
27.
Hermans MH, Ward AC, Antonissen C, et al.
Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia.
Blood.
1998;92:32-39 28. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45:17-23[CrossRef][Medline] [Order article via Infotrieve].
29.
Chono H, Yoshioka H, Ueno M, Kato I.
Removal of inhibitory substances with recombinant fibronectin-CH-296 plates enhances the retroviral transduction efficiency of CD34(+)CD38(
30.
de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S.
Firefly luciferase gene: structure and expression in mammalian cells.
Mol Cell Biol.
1987;7:725-737 31. van der Eb AJ, Graham FL. Assay of transforming activity of tumor virus DNA. Methods Enzymol. 1980;65:826-839[Medline] [Order article via Infotrieve].
32.
Barge RM, de Koning JP, Pouwels K, et al.
Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route.
Blood.
1996;87:2148-2153
33.
Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V.
Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia.
N Engl J Med.
1993;328:614-619
34.
Valk PJ, Vankan Y, Joosten M, et al.
Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2.
J Virol.
1999;73:3595-3602
35.
Ward AC, Smith L, de Koning JP, van Aesch Y, Touw IP.
Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells.
J Biol Chem.
1999;274:14956-14962 36. Yang WM, Yao YL, Seto E. The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor YY1. EMBO J. 2001;20:4814-4825[CrossRef][Medline] [Order article via Infotrieve]. 37. Garcia E, Marcos-Gutierrez C, del Mar LM, Moreno JC, Vidal M. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J. 1999;18:3404-3418[CrossRef][Medline] [Order article via Infotrieve]. 38. David G, Alland L, Hong SH, et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 1998;16:2549-2556[CrossRef][Medline] [Order article via Infotrieve].
39.
Wu WS, Vallian S, Seto E, et al.
The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases.
Mol Cell Biol.
2001;21:2259-2268
40.
Gelmetti V, Zhang J, Fanelli M, et al.
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Mol Cell Biol.
1998;18:7185-7191
41.
Amann JM, Nip J, Strom DK, et al.
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Mol Cell Biol.
2001;21:6470-6483
42.
Shrivastava A, Saleque S, Kalpana GV, et al.
Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc.
Science.
1993;262:1889-1892
43.
Shrivastava A, Yu J, Artandi S, Calame K.
YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels.
Proc Natl Acad Sci U S A.
1996;93:10638-10641 44. Mori A, Higashi H, Hoshikawa Y, et al. Granulocytic differentiation of myeloid progenitor cells by p130, the retinoblastoma tumor suppressor homologue. Oncogene. 1999;18:6209-6221[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. S. Hasemann, I. Damgaard, M. B. Schuster, K. Theilgaard-Monch, A. B. Sorensen, A. Mrsic, T. Krugers, B. Ylstra, F. S. Pedersen, C. Nerlov, et al. Mutation of C/EBP{alpha} predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen Blood, April 15, 2008; 111(8): 4309 - 4321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Affar, F. Gay, Y. Shi, H. Liu, M. Huarte, S. Wu, T. Collins, E. Li, and Y. Shi Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol. Cell. Biol., May 1, 2006; 26(9): 3565 - 3581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wolfler, S. J. Erkeland, C. Bodner, M. Valkhof, W. Renner, C. Leitner, W. Olipitz, M. Pfeilstocker, C. Tinchon, W. Emberger, et al. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome Blood, May 1, 2005; 105(9): 3731 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Denis, A. Benecke, Y. Di Gioia, I. P. Touw, Y. E. Cayre, and P. G. Lutz PRAM-1 Potentiates Arsenic Trioxide-induced JNK Activation J. Biol. Chem., March 11, 2005; 280(10): 9043 - 9048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gronroos, A. A. Terentiev, T. Punga, and J. Ericsson YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress PNAS, August 17, 2004; 101(33): 12165 - 12170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alberich Jorda, N. Rayman, M. Tas, S. E. Verbakel, N. Battista, K. van Lom, B. Lowenberg, M. Maccarrone, and R. Delwel The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner Blood, July 15, 2004; 104(2): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Erkeland, M. Valkhof, C. Heijmans-Antonissen, A. van Hoven-Beijen, R. Delwel, M. H. A. Hermans, and I. P. Touw Large-Scale Identification of Disease Genes Involved in Acute Myeloid Leukemia J. Virol., February 15, 2004; 78(4): 1971 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Bakker, M. Blazquez-Domingo, A. Kolbus, J. Besooyen, P. Steinlein, H. Beug, P. J. Coffer, B. Lowenberg, M. von Lindern, and T. B. van Dijk FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1 J. Cell Biol., January 19, 2004; 164(2): 175 - 184. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
Ra-FITC) (Nordic, Tilburg, The Netherlands).
